H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on RPTX stock, giving a Buy rating on October 17.
Robert Burns’ Buy rating for Repare Therapeutics (RPTX) is driven by several key factors. The data from the ESMO meeting, which showed underwhelming results from competitor Artios’ ART0380, gives Repare a competitive edge. He also notes that ART0380’s objective responses mainly occurred in patients who received a dose above the RP2D, which suggests that the drug may not be as effective at lower doses. Furthermore, Burns highlights ongoing trials evaluating ART0380 as a monotherapy and in combination with chemotherapies, with initial results expected in the coming years.
Burns also points out several upcoming catalysts for Repare, including the initiation of Phase 2 TAPISTRY trial for camonsertib (RP-3500), an investor event on RP-1664 and RP-3467, and initial Phase 1 data for Artios’ DNA polymerase theta inhibitor. He values Repare using a discounted cash flow method, focusing on the two most advanced candidates, RP-3500 and RP-6306. Despite acknowledging several risks, including the failure to obtain regulatory approval, slower-than-expected market uptake due to pricing challenges or competitive pressure, and long-term dilution risk, Burns maintains his Buy rating, suggesting a strong confidence in the company’s potential.
In another report released on October 17, Stifel Nicolaus also maintained a Buy rating on the stock with a $12.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Repare Therapeutics (RPTX) Company Description:
Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Read More on RPTX:
